BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34788361)

  • 21. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
    Rondon-Clavo C; Scordo M; Hilden P; Shah GL; Cho C; Maloy MA; Papadopoulos EB; Jakubowski AA; O'Reilly RJ; Gyurkocza B; Castro-Malaspina H; Tamari R; Shaffer BC; Perales MA; Jaimes EA; Giralt SA
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2517-2522. PubMed ID: 30055353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
    Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
    Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
    Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels.
    Jamani K; Dabas R; Kangarloo SB; Prokopishyn NL; Luider J; Dharmani-Khan P; Khan FM; Daly A; Storek J
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):639-647. PubMed ID: 30572108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
    Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
    Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
    Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
    Yuan J; Pei R; Su W; Cao J; Lu Y
    Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation.
    El-Cheikh J; Devillier R; Dulery R; Massoud R; Al Chami F; Ghaoui N; Moukalled N; Pagliardini T; Marino F; Malard F; Bazarbachi AH; Mohty R; Bazarbachi A; Castagna L; Mohty M; Blaise D
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):617-623. PubMed ID: 32457025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial.
    Büchler M; Longuet H; Lemoine R; Herr F; Gatault P; Thibault G; Ternant D; Foulon C; Pilorge B; Lemay D; Sung C; Halimi JM; Baron C; Lebranchu Y
    Transpl Immunol; 2013 Mar; 28(2-3):120-6. PubMed ID: 23507258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin.
    Dabas R; Jamani K; Kangarloo SB; Dharmani-Khan P; Williamson TS; Ousia S; Durand C; Morris D; Mahoney D; Savoie L; Chaudhry A; Jimenez-Zepeda VH; Khan FM; Daly A; Storek J
    Blood Adv; 2019 May; 3(9):1394-1405. PubMed ID: 31043372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation.
    Nawas MT; Sanchez-Escamilla M; Devlin SM; Maloy MA; Ruiz JD; Sauter CS; Giralt SA; Perales MA; Scordo M
    Blood Adv; 2022 Nov; 6(22):5898-5907. PubMed ID: 35977079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.